Exogenous recombinant interleukin-2 abrogates anterior-chamber-associated immune deviation

Area of Science:

• Ophthalmology
• Immunology
• Transplantation

Background:

• Anterior chamber of the eye exhibits immune privilege, suppressing immune responses like delayed-type hypersensitivity (DTH) and allograft rejection.
• This phenomenon is known as anterior-chamber-associated immune deviation (ACAID).
• ACAID is hypothesized to be the mechanism behind ocular immune privilege.

Purpose of the Study:

• To investigate the role of interleukin 2 (IL-2) in the induction of ACAID.
• To determine if IL-2 administration can prevent ACAID and restore DTH responsiveness.

Main Methods:

• Intracameral inoculation of P815 cells into allogeneic BALB/c recipients to induce ACAID.
• Subcutaneous administration of recombinant IL-2 alongside antigen presentation.
• Monitoring DTH responses and skin allograft rejection.

Main Results:

• Intracameral inoculation of alloantigens induced ACAID, suppressing DTH and allograft rejection.
• Co-administration of IL-2 with alloantigens prevented ACAID and restored DTH responsiveness.
• Exogenous IL-2 was only required during the initial 72 hours after antigen presentation to abrogate ACAID.

Conclusions:

• ACAID induction and antigen-specific DTH suppression are linked to IL-2 deficiency in the early stages of antigen perception.
• Ocular immune privilege may be critically dependent on the local deficiency of IL-2.
• Targeting IL-2 could offer new strategies for managing ocular immune responses and improving transplant outcomes.